Home » Stocks » GRFS

Grifols S.A. (GRFS)

Stock Price: $15.19 USD -0.01 (-0.07%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 14.26B
Revenue (ttm) 6.51B
Net Income (ttm) 754.32M
Shares Out 678.54M
EPS (ttm) 0.48
PE Ratio 31.48
Forward PE 12.17
Dividend $0.46
Dividend Yield 3.01%
Trading Day July 26
Last Price $15.19
Previous Close $15.20
Change ($) -0.01
Change (%) -0.07%
Day's Open 15.17
Day's Range 15.10 - 15.27
Day's Volume 435,868
52-Week Range 14.42 - 19.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

1 week ago - Zacks Investment Research

Singapore's wealth fund GIC agreed to invest around 1 billion dollars in Biomat, a U.S.-based plasma collection company owned by Grifols, thus becoming a strategic investor in the Spanish pharmaceutical...

3 weeks ago - Reuters

BARCELONA, Spain, June 1, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylax...

1 month ago - PRNewsWire

The center will collect real-world data on AMBAR® clinical program - AMBAR® Center combines Grifols' more than 15 years of knowledge researching this devastating disease with the experience of the non-p...

2 months ago - PRNewsWire

BARCELONA, Spain, April 28, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributin...

2 months ago - PRNewsWire

According to the GuruFocus discounted cash flow calculator as of April 21, the following companies have a high margin of safety and have grown their margins over a 10-year period.

Other stocks mentioned: AOS, CBOE, ICLR, MPW
3 months ago - GuruFocus

BARCELONA, Spain, April 15, 2021   /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years...

3 months ago - PRNewsWire

BARCELONA, Spain, April 9, 2021 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United Stat...

3 months ago - PRNewsWire

BARCELONA, Spain, April 2, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years de...

3 months ago - PRNewsWire

BARCELONA, Spain, March 22, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of innovative ...

4 months ago - PRNewsWire

BARCELONA, Spain, March 9, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the hea...

4 months ago - PRNewsWire

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

4 months ago - Zacks Investment Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

5 months ago - Zacks Investment Research

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
5 months ago - Zacks Investment Research

Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.

6 months ago - Zacks Investment Research

BARCELONA, Spain, Jan. 18, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more tha...

6 months ago - PRNewsWire

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
6 months ago - Zacks Investment Research

Good prospects for the global immunoglobulin business. Koru Medical's strategic plan is to reach $ 50M in sales by 2022, a gross margin of 70%, and organic and annual sales growth of + 20%.

6 months ago - Seeking Alpha

Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.

8 months ago - Zacks Investment Research

BARCELONA, Spain, Nov. 16, 2020 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with more...

8 months ago - PRNewsWire

BARCELONA, Spain, Nov. 12, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and provider of technologies and services for...

8 months ago - PRNewsWire

Oligopoly of four companies that control more than 80% of the plasma business. Secular growth trend for population aging.

8 months ago - Seeking Alpha

Fund boosts holding in Buffett's conglomerate, announces management changes

Other stocks mentioned: ROST, BRK.A, BRK.B, HLFFF, IDEXY
8 months ago - GuruFocus

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CI, CWBR, DRRX, PTI
8 months ago - Zacks Investment Research

The Spanish market has gotten crushed with an uptick in COVID-19 deaths. Grifols stock is about where it was when I visited headquarters three years ago.

8 months ago - Seeking Alpha

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
8 months ago - Zacks Investment Research

BARCELONA, Spain, Oct. 9, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than...

9 months ago - PRNewsWire

- The investment includes a fractionation plant with a 1.5 million-liter annual capacity and two purification plants, making Grifols the only large-scale commercial manufacturer of plasma products in Ca...

9 months ago - PRNewsWire

According to the GuruFocus All-in-One Screener, a Premium feature, as of Sept. 30 the following guru-held companies have positive future earnings estimates from Morningstar analysts.

Other stocks mentioned: BXP, CBRE, ESS, KR
9 months ago - GuruFocus

According to the GuruFocus All-in-One Screener, a Premium feature, the following companies have high business predictability ratings and wide margins of safety as of Sept. 28.

Other stocks mentioned: ACGL, AMP, BXP, MLM
9 months ago - GuruFocus

Blood plasma and diagnostics company Grifols SA (NASDAQ: GRFS) is set to completely acquire Alkahest Inc, a biopharmaceutical startup focussed on neurodegenerative and age-related diseases, for $146 mil...

10 months ago - Benzinga

BARCELONA, Spain, and SAN CARLOS, Calif., Sept. 7, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the developmen...

10 months ago - PRNewsWire

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investi...

Other stocks mentioned: ADMA, CERS, KMDA, LMNL, SONN, THMO, TTOO
11 months ago - Benzinga

The results provide more justification for the FDA to grant the substance emergency use authorization.

Other stocks mentioned: TAK
11 months ago - The Motley Fool

BARCELONA, July 28, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 y...

11 months ago - PRNewsWire

- Grifols makes a significant investment to become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 million liters/year - The operation ali...

1 year ago - PRNewsWire

The following companies have grown their earnings per share over a five-year period.

Other stocks mentioned: BIIB, CBPO, HCA, UHS
1 year ago - GuruFocus

Each company has a triad of COVID-19 projects, but they aren't in direct competition.

Other stocks mentioned: NVS
1 year ago - The Motley Fool

Antibodies of recovered patients can help treat people who are infected with the novel coronavirus.

Other stocks mentioned: EBS, TAK
1 year ago - The Motley Fool

Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.

Other stocks mentioned: JNJ, MRK, RDY, RGEN, TAK, ZTS
1 year ago - InvestorPlace

Pharmaceutical stocks dipped by a double-digit percentage in the first four months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.

Other stocks mentioned: ABBV, AGN, BMY, JAZZ, MRK, NVO, SNY ...
1 year ago - Investors Business Daily

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
1 year ago - Zacks Investment Research

Grifols (GRFS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Grifols (NASDAQ: GRFS) shares are trading higher on Thursday. The company announced it's working with the U.S.

1 year ago - Benzinga

Grifols (GRFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

GRFS vs. IONS: Which Stock Is the Better Value Option?

Other stocks mentioned: IONS
1 year ago - Zacks Investment Research

GRFS vs. IONS: Which Stock Is the Better Value Option?

Other stocks mentioned: IONS
1 year ago - Zacks Investment Research

Shares of Grifols popped in massive volume Friday after the Spain-based pharmaceutical company gained Food and Drug Administration approval for an immunodeficiency treatment.

2 years ago - Investors Business Daily

GRFS vs. ORINY: Which Stock Is the Better Value Option?

2 years ago - Zacks Investment Research

About GRFS

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutica... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
May 17, 2006
Stock Exchange
NASDAQ
Ticker Symbol
GRFS
Full Company Profile

Financial Performance

In 2020, Grifols S.A.'s revenue was 5.34 billion, an increase of 4.73% compared to the previous year's 5.10 billion. Earnings were 618.55 million, a decrease of -1.06%.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Grifols S.A. stock is "Buy." The 12-month stock price forecast is 28.62, which is an increase of 88.41% from the latest price.

Price Target
$28.62
(88.41% upside)
Analyst Consensus: Buy